Enliven Therapeutics (NASDAQ:ELVN) Upgraded to Hold at Zacks Research

Key Points

• Zacks Research upgraded Enliven Therapeutics from “strong sell” to “hold.” Analyst sentiment overall remains a “Moderate Buy,” with 10 Buy, one Hold, and one Sell rating and an average price target of $75.44.
• Enliven reported a quarterly loss of $0.36 per share, better than the consensus estimate of a $0.45 loss. The stock opened at $48.31 and has traded between $14.78 and $62.32 over the past year.
• Company insiders sold 31,054 shares worth about $1.49 million over the past 90 days, while institutional investors own 95.08% of the stock.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating in a report released on Wednesday, Zacks reports.

Other equities analysts have also issued reports about the stock. HC Wainwright raised their price objective on shares of Enliven Therapeutics from $65.00 to $73.00 and gave the company a "buy" rating in a research report on Monday, October 19th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Enliven Therapeutics in a report on Thursday, October 15th. Wall Street Zen raised shares of Enliven Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, November 7th. Stifel Nicolaus increased their target price on shares of Enliven Therapeutics from $80.00 to $82.00 and gave the stock a "buy" rating in a research note on Thursday, August 6th. Finally, The Goldman Sachs Group raised their price target on shares of Enliven Therapeutics from $67.00 to $80.00 and gave the company a "buy" rating in a report on Thursday, August 6th. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $75.44.

Enliven Therapeutics Price Performance

Shares of ELVN opened at $48.31 on Wednesday. The stock's 50-day simple moving average is $46.65 and its 200 day simple moving average is $43.56. Enliven Therapeutics has a 52-week low of $14.78 and a 52-week high of $62.32.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.09. Sell-side analysts anticipate that Enliven Therapeutics will post -1.70 earnings per share for the current year.

Insider Activity at Enliven Therapeutics

In other Enliven Therapeutics news, Director J. Scott Garland sold 13,000 shares of the company's stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $46.67, for a total value of $606,710.00. Following the completion of the sale, the director owned 13,000 shares of the company's stock, valued at $606,710. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Benjamin Hohl sold 6,018 shares of the stock in a transaction that occurred on Monday, October 19th. The shares were sold at an average price of $38.48, for a total transaction of $231,572.64. Following the transaction, the chief financial officer owned 38,000 shares in the company, valued at $1,462,240. The trade was a 13.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 31,054 shares of company stock valued at $1,493,823. 3.00% of the stock is owned by insiders.

Institutional Investors Weigh In On Enliven Therapeutics

A number of institutional investors have recently made changes to their positions in the business. BlackRock Inc. purchased a new position in Enliven Therapeutics in the 2nd quarter worth $221,255,000. First Light Asset Management LLC lifted its stake in Enliven Therapeutics by 574.1% in the second quarter. First Light Asset Management LLC now owns 1,360,750 shares of the company's stock worth $69,058,000 after purchasing an additional 1,158,883 shares during the last quarter. Pictet Asset Management Holding SA boosted its position in Enliven Therapeutics by 14.1% during the third quarter. Pictet Asset Management Holding SA now owns 1,325,740 shares of the company's stock valued at $60,772,000 after buying an additional 163,956 shares during the period. Assenagon Asset Management S.A. boosted its position in Enliven Therapeutics by 276.4% during the third quarter. Assenagon Asset Management S.A. now owns 1,153,973 shares of the company's stock valued at $52,898,000 after buying an additional 847,399 shares during the period. Finally, Rock Springs Capital Management LP boosted its position in Enliven Therapeutics by 3.5% during the first quarter. Rock Springs Capital Management LP now owns 826,500 shares of the company's stock valued at $32,399,000 after buying an additional 28,095 shares during the period. Hedge funds and other institutional investors own 95.08% of the company's stock.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule medicines for cancer. Its research centers on precision oncology, with drug candidates designed to target specific proteins involved in tumor growth. The company's pipeline has included ELVN-001, an investigational BCR-ABL1 inhibitor being studied for chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor developed for cancers driven by HER2. Enliven is based in Boulder, Colorado.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.